Zacks Research Has Positive Forecast for VRTX Q2 Earnings

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Analysts at Zacks Research boosted their Q2 2025 earnings estimates for shares of Vertex Pharmaceuticals in a research report issued on Wednesday, October 23rd. Zacks Research analyst R. Department now anticipates that the pharmaceutical company will post earnings per share of $4.09 for the quarter, up from their prior estimate of $4.04. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is ($2.11) per share. Zacks Research also issued estimates for Vertex Pharmaceuticals’ Q3 2025 earnings at $3.97 EPS, Q4 2025 earnings at $4.01 EPS, FY2025 earnings at $15.93 EPS, Q1 2026 earnings at $4.08 EPS and Q3 2026 earnings at $4.44 EPS.

VRTX has been the topic of several other research reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Vertex Pharmaceuticals in a research note on Friday, July 26th. Piper Sandler lifted their target price on shares of Vertex Pharmaceuticals from $500.00 to $535.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. JPMorgan Chase & Co. boosted their price target on shares of Vertex Pharmaceuticals from $505.00 to $510.00 and gave the company an “overweight” rating in a research report on Monday, August 5th. Cantor Fitzgerald reissued an “overweight” rating and set a $480.00 price target on shares of Vertex Pharmaceuticals in a research report on Tuesday, October 8th. Finally, Morgan Stanley boosted their price target on shares of Vertex Pharmaceuticals from $462.00 to $474.00 and gave the company an “equal weight” rating in a research report on Tuesday, October 1st. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating and seventeen have assigned a buy rating to the company. According to MarketBeat.com, Vertex Pharmaceuticals has an average rating of “Hold” and an average price target of $492.92.

Vertex Pharmaceuticals Trading Up 1.2 %

Shares of VRTX opened at $477.70 on Thursday. Vertex Pharmaceuticals has a 52-week low of $341.90 and a 52-week high of $510.64. The company has a quick ratio of 2.26, a current ratio of 2.52 and a debt-to-equity ratio of 0.02. The firm’s fifty day moving average is $475.60 and its two-hundred day moving average is $461.36. The stock has a market cap of $123.27 billion, a PE ratio of 31.00 and a beta of 0.40.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Thursday, August 1st. The pharmaceutical company reported ($12.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($12.54) by ($0.29). Vertex Pharmaceuticals had a negative net margin of 4.74% and a negative return on equity of 2.45%. The company had revenue of $2.65 billion during the quarter, compared to analyst estimates of $2.66 billion. During the same period in the prior year, the business posted $3.53 EPS. Vertex Pharmaceuticals’s revenue was up 6.1% compared to the same quarter last year.

Institutional Trading of Vertex Pharmaceuticals

A number of large investors have recently made changes to their positions in VRTX. Northwest Investment Counselors LLC acquired a new position in Vertex Pharmaceuticals in the third quarter valued at approximately $25,000. Annapolis Financial Services LLC acquired a new position in Vertex Pharmaceuticals in the first quarter valued at approximately $27,000. Highline Wealth Partners LLC acquired a new position in Vertex Pharmaceuticals in the third quarter valued at approximately $27,000. GHP Investment Advisors Inc. acquired a new position in Vertex Pharmaceuticals in the second quarter valued at approximately $29,000. Finally, Stephens Consulting LLC acquired a new position in Vertex Pharmaceuticals in the second quarter valued at approximately $31,000. 90.96% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Vertex Pharmaceuticals news, Director Bruce I. Sachs sold 5,295 shares of the business’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $508.00, for a total transaction of $2,689,860.00. Following the sale, the director now directly owns 40,000 shares in the company, valued at $20,320,000. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Bruce I. Sachs sold 5,295 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $508.00, for a total transaction of $2,689,860.00. Following the sale, the director now directly owns 40,000 shares in the company, valued at approximately $20,320,000. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Sangeeta N. Bhatia sold 646 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $500.00, for a total transaction of $323,000.00. Following the sale, the director now owns 4,435 shares in the company, valued at $2,217,500. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 12,005 shares of company stock worth $5,988,066 over the last three months. Company insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.